These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 32850360)

  • 1. Circulating Tumor DNA as a Potential Marker to Detect Minimal Residual Disease and Predict Recurrence in Pancreatic Cancer.
    Jiang J; Ye S; Xu Y; Chang L; Hu X; Ru G; Guo Y; Yi X; Yang L; Huang D
    Front Oncol; 2020; 10():1220. PubMed ID: 32850360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer.
    Eckhoff AM; Kanu E; Fletcher A; Bao M; Aushev VN; Spickard E; Nussbaum DP; Allen PJ
    Ann Surg Oncol; 2024 Mar; 31(3):1444-1446. PubMed ID: 38170407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical resection.
    Hata T; Mizuma M; Motoi F; Ohtsuka H; Nakagawa K; Morikawa T; Unno M
    J Hepatobiliary Pancreat Sci; 2023 Jun; 30(6):815-824. PubMed ID: 36408698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parallel Analysis of Pre- and Postoperative Circulating Tumor DNA and Matched Tumor Tissues in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Cohort Study.
    Lee JS; Han Y; Yun WG; Kwon W; Kim H; Jeong H; Seo MS; Park Y; Cho SI; Kim H; Kim JY; Seong MW; Jang JY; Park SS
    Clin Chem; 2022 Dec; 68(12):1509-1518. PubMed ID: 36177751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma.
    Botta GP; Abdelrahim M; Drengler RL; Aushev VN; Esmail A; Laliotis G; Brewer CM; George GV; Abbate SM; Chandana SR; Tejani MA; Malla M; Bansal D; Rivero-Hinojosa S; Spickard E; McCormick N; Cecchini M; Lacy J; Fei N; Kasi PM; Kasi A; Dayyani F; Hanna DL; Sharma S; Malhotra M; Aleshin A; Liu MC; Jurdi A
    Oncologist; 2024 Oct; 29(10):859-869. PubMed ID: 39022993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic utility of preoperative and postoperative KRAS-mutated circulating tumor DNA (ctDNA) in resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
    Alqahtani A; Alloghbi A; Coffin P; Yin C; Mukherji R; Weinberg BA
    Surg Oncol; 2023 Dec; 51():102007. PubMed ID: 37852124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer.
    Schøler LV; Reinert T; Ørntoft MW; Kassentoft CG; Árnadóttir SS; Vang S; Nordentoft I; Knudsen M; Lamy P; Andreasen D; Mortensen FV; Knudsen AR; Stribolt K; Sivesgaard K; Mouritzen P; Nielsen HJ; Laurberg S; Ørntoft TF; Andersen CL
    Clin Cancer Res; 2017 Sep; 23(18):5437-5445. PubMed ID: 28600478
    [No Abstract]   [Full Text] [Related]  

  • 9. Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer.
    Feng W; Jia N; Jiao H; Chen J; Chen Y; Zhang Y; Zhu M; Zhu C; Shen L; Long W
    J Transl Med; 2021 Feb; 19(1):51. PubMed ID: 33536036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Tumor DNA as a Prognostic Biomarker in Localized Non-small Cell Lung Cancer.
    Peng M; Huang Q; Yin W; Tan S; Chen C; Liu W; Tang J; Wang X; Zhang B; Zou M; Li J; Su W; Wang L; Chin L; Yu F
    Front Oncol; 2020; 10():561598. PubMed ID: 33042842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
    Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
    Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma.
    Strijker M; Soer EC; de Pastena M; Creemers A; Balduzzi A; Beagan JJ; Busch OR; van Delden OM; Halfwerk H; van Hooft JE; van Lienden KP; Marchegiani G; Meijer SL; van Noesel CJ; Reinten RJ; Roos E; Schokker S; Verheij J; van de Vijver MJ; Waasdorp C; Wilmink JW; Ylstra B; Besselink MG; Bijlsma MF; Dijk F; van Laarhoven HW
    Int J Cancer; 2020 Mar; 146(5):1445-1456. PubMed ID: 31340061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma.
    Nitschke C; Markmann B; Walter P; Badbaran A; Tölle M; Kropidlowski J; Belloum Y; Goetz MR; Bardenhagen J; Stern L; Tintelnot J; Schönlein M; Sinn M; van der Leest P; Simon R; Heumann A; Izbicki JR; Pantel K; Wikman H; Uzunoglu FG
    Clin Chem; 2023 Mar; 69(3):295-307. PubMed ID: 36644936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma.
    Fu Y; Xu Y; Liu W; Zhang J; Wang F; Jian Q; Huang G; Zou C; Xie X; Kim AH; Mathios D; Pang F; Li F; Wang K; Shen J; Yin J
    EClinicalMedicine; 2024 Jul; 73():102697. PubMed ID: 39022798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection.
    Xu Y; Cai J; Zhong K; Wen Y; Cai L; He G; Liao H; Zhang C; Fu S; Chen T; Cai J; Zhong X; Chen C; Huang M; Cheng Y; Pan M
    Front Oncol; 2023; 13():1119744. PubMed ID: 36959801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diagnostic and prognostic usage of circulating tumor DNA in operable hepatocellular carcinoma.
    An Y; Guan Y; Xu Y; Han Y; Wu C; Bao C; Zhou B; Wang H; Zhang M; Liu W; Qiu L; Han Z; Chen Y; Xia X; Wang J; Liu Z; Huang W; Yi X; Huang J
    Am J Transl Res; 2019; 11(10):6462-6474. PubMed ID: 31737198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor DNA analysis predicts recurrence and avoids unnecessary adjuvant chemotherapy in I-IV colorectal cancer.
    Fan W; Xia Z; Chen R; Lin D; Li F; Zheng Y; Luo J; Xiong Y; Yu P; Gao W; Gong Y; Zhang F; Zhang S; Li L
    Ther Adv Med Oncol; 2024; 16():17588359231220607. PubMed ID: 38282662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
    Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
    J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating Tumor DNA as a Sensitive Marker in Patients Undergoing Irreversible Electroporation for Pancreatic Cancer.
    Lin M; Alnaggar M; Liang S; Chen J; Xu K; Dong S; Du D; Niu L
    Cell Physiol Biochem; 2018; 47(4):1556-1564. PubMed ID: 29940591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
    Lee JS; Rhee TM; Pietrasz D; Bachet JB; Laurent-Puig P; Kong SY; Takai E; Yachida S; Shibata T; Lee JW; Park HC; Zang DY; Jeon K; Lee J; Kim M; Kim HS; Kang HJ; Lee YK
    Sci Rep; 2019 Nov; 9(1):16971. PubMed ID: 31740696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.